| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(1 year, 1 month from now) | |
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(3 years from now) | |
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(9 years from now) | |
| US11504370 | SEAGEN | NA |
Mar, 2033
(9 years from now) | |
| US11207324 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(14 years from now) | |
Tukysa is owned by Seagen.
Tukysa contains Tucatinib.
Tukysa has a total of 6 drug patents out of which 0 drug patents have expired.
Tukysa was authorised for market use on 17 April, 2020.
Tukysa is available in tablet;oral dosage forms.
Tukysa can be used as treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer, combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing unresectable or metastatic colorectal cancer.
Drug patent challenges can be filed against Tukysa from 2024-04-17.
The generics of Tukysa are possible to be released after 27 April, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 19, 2030 |
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| New Indication (I) | Jan 19, 2026 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 2024-04-17
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing...
Dosage: TABLET;ORAL
TUKYSA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic